Pharmacologically active stigmast-4-en-3-one, the maximum formation of which (93.4 %) was achieved in the presence of n-hexadecane and palmitic acid, was produced by biotransformation of β-sitosterol (6 g/L) using rhodococcus cells. β-Sitosterol was added to the incubation medium as a mixture with β-cyclodextrin and Tween-80. The biotransformation processing conditions were optimized for β-sitosterol at high concentrations (10 g/L) using R. erythropolis IEGM 90 cells to catalyze formation of stigmast-4-en-3-one (75 %).
具有药理活性的 stigmast-4-en-3-one,其最大形成量 (93.4 %) 在
正十六烷和
棕榈酸存在下实现,是通过使用红球菌
生物转化
β-谷甾醇 (6 g/L) 产生的细胞。将
β-谷甾醇作为与 β-
环糊精和 Tween-80 的混合物添加到培养介质中。使用红平红球菌 I
EGM 90 细胞对高浓度
β-谷甾醇 (10 g/L) 的
生物转化处理条件进行优化,以催化 stigmast-4-en-3-one (75%) 的形成。